LONDON and NEW YORK — October 16, 2025 — Leads & Copy — OKYO Pharma Limited (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 210,000 of the company’s ordinary shares on NASDAQ, bringing his total holding to 10,382,677 shares. The company is an ophthalmology-focused bio-pharmaceutical company developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy.
Urcosimod, formerly called OK-101, is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Developed using a membrane-anchored-peptide technology, it is a novel long-acting drug candidate for treating ocular diseases. It has demonstrated anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain. A Phase 2 trial of urcosimod to treat neuropathic corneal pain patients was just completed by OKYO.
OKYO Pharma Limited is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market.
Paul Spencer
Business Development & Investor Relations
+44 (0)20 7495 2379
Source: OKYO Pharma Limited
